All Industries

Top Therapeutics Companies

203 Therapeutics companies, sorted by total funding raised.

Caribou BiosciencesIPO

Clinical-stage biopharmaceutical company developing genome-edited allogeneic CAR-T cell therapies...

Berkeley, United States51–200Biotech, Life Sciences
Corporate Round·$181.0M·Jul 2023
Big Health

Digital therapeutics company providing clinically proven cognitive behavioral therapy programs fo...

San Francisco, United States51–200Digital Health, Therapeutics
Venture Unknown·$173.4M·Mar 2026
Alentis Therapeutics

Clinical-stage biotech developing anti‑Claudin-1 ADCs and antibodies for cancer and organ fibrosis.

Basel, Switzerland51–200Biotech, Drug Discovery
Series C·$172.0M·Apr 2023
Congruence Therapeutics

Computational drug discovery company designing small-molecule correctors for diseases caused by p...

Montreal, Canada11–50Biotech, Drug Discovery
Series B·$169.0M·Mar 2026
AviadoBio

AviadoBio is a biotechnology company developing transformative gene therapies for neurodegenerati...

London, United Kingdom51–200Biotech, Genomics
Series B·$168.5M·Apr 2025
ARMO BioSciencesClosed

Late-stage immuno-oncology company developing pegilodecakin (AM0010) and immune-modulating biolog...

Redwood City, United States11–50Biotech, Therapeutics
Series C·$167.0M·Aug 2017
Editas MedicineIPO

Clinical-stage biotechnology company developing CRISPR-based genomic medicines for people with se...

Cambridge, United States201–500Biotech, Genomics
Series B·$163.0M·Aug 2015
AkouosAcquired

Akouos is a biotechnology company focused on restoring and preserving hearing.

Boston, United States51–200Biotech, Therapeutics
Series B·$162.5M·Mar 2020
Addex TherapeuticsIPO

Addex Therapeutics is a biopharmaceutical company focused on the development of novel, orally ava...

Plan-les-Ouates, Switzerland11–50Biopharmaceutical, Biotech
Extension Round·$155.9M·Aug 2022
EpizymeIPO

Biopharmaceutical company that is creating innovative drugs for major diseases based on important...

Cambridge, United States201–500Biotech, Drug Discovery
Growth Equity·$154.0M·Nov 2019
Sagimet BiosciencesIPO

A clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat impo...

San Mateo, United States11–50Biotech, Drug Discovery
Growth Equity·$153.5M·Feb 2021
Avencell

Clinical-stage biopharma developing switchable and allogeneic CAR‑T cell therapies for hard-to-tr...

Watertown, United States51–200Biotech, Genomics
Grant·$152.0M·Jun 2025
Magenta TherapeuticsAcquired

Clinical-stage biotechnology company developing novel medicines to harness the curative power of ...

Cambridge, United States51–200Biotech, Therapeutics
Series C·$150.5M·Apr 2018
Shape Therapeutics

A development stage biotechnology company based in Seattle WA and San Diego CA that is establishi...

Seattle, United States51–200RNA, biotech
Series A·$147.5M
Ideaya BiosciencesIPO

Clinical-stage precision medicine oncology company developing targeted therapeutics using molecul...

South San Francisco, United States201–500Biotech, Drug Discovery
Series A·$140.0M·Jul 2024
ArdelyxIPO

Focused on the discovery and development of novel therapeutics acting exclusively in the gastroin...

Fremont, United States201–500Biopharmaceutical, Therapeutics
Private Equity·$140.0M·Jul 2016
Allay Therapeutics

Ultra-sustained analgesic products for post-surgical pain management.

San Jose, United States11–50Biotech, Pain Management
Series D·$133.5M·Jun 2025
SurrozenIPO

Surrozen is a clinical-stage biotech developing Wnt pathway-based regenerative medicines, with a ...

South San Francisco, United States11–50Biotech, Therapeutics
Series C·$133.0M·Jun 2020
Pretzel Therapeutics

Develops therapeutics that restore mitochondrial function for rare and common diseases using geno...

Waltham, United States11–50Biotech, Drug Discovery
Venture Unknown·$131.8M·Aug 2024
CHARM Therapeutics

AI-driven biotech developing next-generation menin inhibitors and small-molecule therapeutics for...

London, United Kingdom11–50Life Sciences, Biotech
Series B·$130.0M·Sep 2025
Monte Rosa TherapeuticsIPO

Monte Rosa Therapeutics is a biotechnology company developing molecular glues to degrade disease-...

Boston, United States51–200Biotech, Drug Discovery
Series C·$127.5M·Mar 2021
Gilgamesh Pharmaceuticals

Gilgamesh Pharmaceuticals, a Clinical stage biotechnology company…

New York, United States11–50Healthcare, Mental Health
Series A·$126.0M·Mar 2026
OnCusp Therapeutics

Clinical-stage biopharma developing targeted oncology therapeutics and ADCs to advance treatments...

Princeton, United States11–50Biotech, Healthcare
Series A·$125.0M·Jan 2024
Gate Bioscience

Biotechnology company developing oral small-molecule ‘molecular gates’ to eliminate disease-causi...

California, United States11–50Biotech, Drug Discovery
Series B·$125.0M·Nov 2025
Epic Bio

Epic Bio (now Epicrispr Biotechnologies) develops epigenetic gene therapies using ultracompact CR...

South San Francisco, United States11–50Biotech, Therapeutics
Series B·$123.0M·Mar 2025